Clinical cancer nanomedicines

IF 10.5 1区医学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Journal of Controlled Release Pub Date : 2025-06-27 DOI:10.1016/j.jconrel.2025.113991

Roger M. Pallares, Roman A. Barmin, Alec Wang, Fabian Kiessling, Twan Lammers

引用次数: 0

Abstract

Over the past three decades, nanomedicines have become increasingly common in the treatment of cancer. By altering the pharmacokinetics and biodistribution profiles of drugs, nanomedicines help to reduce toxicity and enhance overall therapeutic indices. This manuscript reviews the current landscape of nanomedicines for cancer therapy, highlighting the formulations that have successfully reached clinical use as well as those being investigated in clinical trials. These formulations include “conventional” nanomedicines that rely on passive drug delivery, as well as newer formulations that are stimuli-responsive, actively targeted, used for combination therapies, or intended to improve immunotherapy. By critically analyzing the clinical progress of nanomedicines, we aim to identify the key features that drive successful translation and lead to clinical impact.

Abstract Image

查看原文本刊更多论文

临床癌症纳米药物

在过去的三十年里，纳米药物在治疗癌症方面变得越来越普遍。通过改变药物的药代动力学和生物分布特征，纳米药物有助于降低毒性并提高整体治疗指标。本文回顾了纳米药物治疗癌症的现状，重点介绍了已经成功达到临床应用的配方以及正在临床试验中研究的配方。这些制剂包括依赖被动给药的“传统”纳米药物，以及具有刺激反应性、积极靶向性、用于联合治疗或旨在改善免疫治疗的新制剂。通过批判性地分析纳米药物的临床进展，我们的目标是确定驱动成功转化并导致临床影响的关键特征。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Controlled Release 医学-化学综合

CiteScore

18.50

自引率

5.60%

发文量

700

审稿时长

39 days

期刊介绍： The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System. Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries. Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.